Beta 2 Adrenergic Receptor Stabilization via EGLN3 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate the expression and activity of β2 adrenergic receptors, leading to various disorders such as heart failure and asthma due to down-regulation of these receptors.
Innovation Solution
Administering inhibitors of the Von Hippel-Lindau tumor suppressor protein (pVHL) or its associated enzyme EGLN3, such as succinate dehydrogenase compounds or specific siRNAs, to prevent the ubiquitylation and degradation of β2ARs, thereby increasing their expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If continuous agonist stimulation is applied to increase β2AR activity, then cardiac contractility and physiological function are improved, but β2AR expression decreases due to ubiquitylation and degradation
Solution Approach 1:
The patent converts the harmful effect of continuous agonist stimulation (which causes receptor down-regulation) into a beneficial outcome by using this same stimulation to trigger the recruitment of protective factors (such as HIF-1α and pVHL) that prevent complete receptor degradation. The continuous stimulation is reframed as a mechanism to activate protective pathways that maintain receptor expression.
Solution Approach 2:
The patent introduces intermediary molecules (HIF-1α, pVHL, and other protective factors) that mediate between the agonist stimulation and the β2AR receptor. These intermediaries act as protective shields that prevent direct degradation of the receptor while allowing the beneficial signaling effects to continue.
2Quantity of substance
If β2AR expression is increased to treat disorders like heart failure and asthma, then physiological function improves, but current methods to regulate expression are insufficient
Solution Approach 1:
The patent employs self-service mechanisms where the body's own signaling pathways (agonist stimulation) are harnessed to recruit protective factors that maintain β2AR expression. The system uses its endogenous resources (HIF-1α, pVHL, and other protective proteins) to regulate receptor expression without requiring external intervention.
Solution Approach 2:
The patent changes the regulatory parameters by shifting the control mechanism from direct receptor stabilization to modulation of protective factor expression. By altering the expression levels of HIF-1α, pVHL, and other protective factors, the system indirectly regulates β2AR expression in a more controllable and sustainable manner.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats disorders associated with decreased β2AR expression or activity, improving cardiac contractility, respiratory function, and addressing conditions like asthma and pulmonary edema by maintaining or enhancing β2AR levels.
Implementation Method 1
The interaction of pVHL with the β2AR is dependent on proline hydroxylation, and the dioxygenase EGLN3 interacts directly with the β2AR to serve as an endogenous β2AR prolyl hydroxylase.
Implementation Method 2
Following hydroxylation of the β2AR, the pVHL-E3 ligase complex is recruited to and ubiquitylates the β2AR, promoting its down-regulation via proteosomal degradation.
Implementation Method 3
The inventors of the present application have discovered that the interaction between EGLN3 and β2AR can be manipulated to regulate the expression and activity of β2ARs.
Data Source
AI summary
This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of β2 adrenergic receptors or need for increased 132 adrenergic receptor activity.